Skip to main content

Publications While a Duke Urologic Oncology Fellow

Jorge Caso, MD

Tsivian M, Moreira DM, Caso JR, Mouraviev V, Madden JF, Bratslavsky G, Robertson CN, Albala DM, Polascik TJ. Predicting occult multifocality of renal cell carcinoma. Eur Urol. 2010 Jul;58(1):118-26. doi: 10.1016/j.eururo.2010.03.011. Epub 2010 Mar 17. PubMed PMID: 20346577.

Caso JR, Mouraviev V, Tsivian M, Polascik TJ, Moul JW. Prostate cancer: an evolving paradigm. J Endourol. 2010 May;24(5):805-9. doi: 10.1089/end.2009.0539. PubMed PMID: 20367442.

Caso JR, Tsivian M, Mouraviev V, Polascik TJ, Moul JW. Pathological T2 sub-divisions as a prognostic factor in the biochemical recurrence of prostate cancer. BJU Int. 2010 Dec;106(11):1623-7. doi: 10.1111/j.1464-410X.2010.09439.x.  PubMed PMID: 20553260.

Caso JR, Tsivian M, Mouraviev V, Polascik TJ. Predicting biopsy-proven prostate cancer recurrence following cryosurgery. Urol Oncol. 2012 Jul-Aug;30(4):391-5. doi: 10.1016/j.urolonc.2010.04.001. Epub 2010 Sep 9. PubMed  PMID: 20826095.

Kimura M, Rabbani Z, Mouraviev V, Tsivian M, Caso J, Satoh T, Baba S, Vujaskovic Z, Baust JM, Baust JG and Polascik TJ:  Role of vitamin D3 as a sensitizer to cryoablation in a murine prostate cancer model: preliminary in vivo study. Urology, 2010 76(3): 764.e14-20.

Tsivian M, Mouraviev V, Albala DM, Caso JR, Robertson CN, Madden JF, Polascik  TJ. Clinical predictors of renal mass pathological features. BJU Int. 2011 Mar;107(5):735-740. doi: 10.1111/j.1464-410X.2010.09629.x. Epub 2010 Nov 5. PubMed PMID: 21054752.

Kimura M, Donatucci CF, Tsivian M, Caso JR, Moreira DM, Mouraviev V, Satoh T,  Baba S, Polascik TJ. On-demand use of erectile aids in men with preoperative erectile dysfunction treated by whole gland prostate cryoablation. Int J Impot Res. 2011 Mar-Apr;23(2):49-55. doi: 10.1038/ijir.2011.3. Epub 2011 Mar 3. PubMed  PMID: 21368768.

Tsivian M, Moreira DM, Caso JR, Mouraviev V, Polascik TJ. Cigarette smoking is associated with advanced renal cell carcinoma. J Clin Oncol. 2011 May 20;29(15):2027-31. doi: 10.1200/JCO.2010.30.9484. Epub 2011 Apr 18. PubMed PMID:  21502558.

Caso JR, Tsivian M, Mouraviev V, Kimura M, Polascik TJ. Complications and postoperative events after cryosurgery for prostate cancer. BJU Int. 2012 Mar;109(6):840-5. doi: 10.1111/j.1464-410X.2011.10423.x. Epub 2011 Aug 22. PubMed PMID: 21883827.

Tsivian M, Caso J, Kimura M and Polascik TJ: Renal function outcomes after laparoscopic renal cryoablation.  J Endourology 25(8): 1287-1291, 2011.

Tsivian M, Kim CY, Caso JR, Rosenberg MD, Nelson RC, Polascik TJ. Contrast enhancement on computed tomography after renal cryoablation: an evidence of treatment failure? J Endourol. 2012 Apr;26(4):330-5. doi: 10.1089/end.2011.0337.  Epub 2012 Jan 4. PubMed PMID: 22070179.

Kimura M, Caso JR, Bañez LL, Koontz BF, Gerber L, Senocak C, Donatucci CF, Vujaskovic Z, Moul JW, Polascik TJ. Predicting participation in and successful outcome of a penile rehabilitation programme using a phosphodiesterase type 5 inhibitor with a vacuum erection device after radical prostatectomy. BJU Int. 2012 Dec; 110(11 Pt C):E931-8. doi: 10.1111/j.1464-410X.2012.11168.x. Epub 2012 Apr 23. PubMed PMID: 22520165.

Tsivian M, Caso JR, Kimura M, and Polascik TJ: Renal tumors in solid organ recipients: clinical and pathologic features.  Urologic Oncology, 31(2): 255-8, 2013, (2011 Jun 28 [Epub ahead of print].

Michael R. Abern, MD

Tsivian M, Abern MR and Polascik TJ: Cigarette smoking and kidney cancer: benefits of smoking cessation.  Int J Clin Rev 12:9, 2011.

Abern MR, Tsivian M, Polascik TJ. Refining treatment for the men who need it: lessons from the PIVOT trial. Transl Androl Urol. 2013 Jun;2(2):82-4. doi: 10.3978/j.issn.2223-4683.2012.09.05. PubMed PMID: 26816728; PubMed Central PMCID: PMC4708217.

Inman BA, Abern MR. Maintenance bacillus Calmette-Guérin: why is there continued debate? Eur Urol. 2013 Oct;64(4):586-7. doi: 10.1016/j.eururo.2013.05.055. Epub 2013 Jun 11. PubMed PMID: 23773556.

Abern MR, Tsivian M, Coogan CL, Kaufman HL, Polascik TJ. Characteristics of patients diagnosed with both melanoma and renal cell cancer. Cancer Causes Control. 2013 Nov;24(11):1925-33. doi: 10.1007/s10552-013-0267-0. Epub 2013 Jul 30. PubMed PMID: 23897487.

Owusu RA, Abern MR, Inman BA. Hyperthermia as adjunct to intravesical chemotherapy for bladder cancer. Biomed Res Int. 2013;2013:262313. doi: 10.1155/2013/262313. Epub 2013 Sep 1. Review. PubMed PMID: 24073396; PubMed Central PMCID: PMC3773892.

Allott EH, Abern MR, Gerber L, Keto CJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Moorman PG, Freedland SJ. Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database. Prostate Cancer Prostatic Dis. 2013 Dec;16(4):391-7. doi: 10.1038/pcan.2013.48. Epub 2013 Oct 8. PubMed PMID: 24100644; PubMed Central PMCID: PMC3830588.

Abern MR, Owusu R, Inman BA. Clinical performance and utility of a DNA methylation urine test for bladder cancer. Urol Oncol. 2014 Jan;32(1):51.e21-6. doi: 10.1016/j.urolonc.2013.08.003. PubMed PMID: 24360662.

Abern MR, Terris MK, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Freedland  SJ. The impact of pathologic staging on the long-term oncologic outcomes of patients with clinically high-risk prostate cancer. Cancer. 2014 Jun 1;120(11):1656-62. doi: 10.1002/cncr.28647. Epub 2014 Mar 19. PubMed PMID: 24647966.

Wang HH, Abern MR, Cost NG, Chu DI, Ross SS, Wiener JS, Routh JC. Use of nephron sparing surgery and impact on survival in children with Wilms tumor: a SEER analysis. J Urol. 2014 Oct;192(4):1196-202. doi: 10.1016/j.juro.2014.04.003. Epub 2014 Apr 13. PubMed PMID: 24735935; PubMed Central PMCID: PMC4194219.

Abern MR, Tsivian M, Polascik TJ. Focal therapy of prostate cancer: evidence-based analysis for modern selection criteria. Curr Urol Rep. 2012 Apr;13(2):160-9. doi: 10.1007/s11934-012-0241-5. Review. PubMed PMID: 22298223.

Tsivian M, Abern MR, Polascik TJ. Prostate cancer treatment unblinded. Lancet Oncol. 2012 Jun;13(6):567-8. doi: 10.1016/S1470-2045(12)70136-5. Epub 2012 Apr 17. PubMed PMID: 22512845.
Abern MR, Allott EH, Freedland SJ. C-reactive protein as a prognostic marker  FOR mCRPC. BJU Int. 2012 Dec;110(11 Pt B):E469. doi: 10.1111/j.1464-410X.2012.11156.x. Epub 2012 Apr 23. PubMed PMID: 22519959.

Abern MR, Dude AM, Tsivian M, Coogan CL. The characteristics of bladder cancer after radiotherapy for prostate cancer. Urol Oncol. 2013 Nov;31(8):1628-34. doi: 10.1016/j.urolonc.2012.04.006. Epub 2012 May 9. PubMed PMID: 22575239.

Abern MR, Tsivian M, Polascik TJ, Coogan CL. Characteristics and outcomes of  tumors arising from the distal nephron. Urology. 2012 Jul;80(1):140-6. doi: 10.1016/j.urology.2012.03.034. Epub 2012 May 23. PubMed PMID: 22626576.

Abern MR, Freedland SJ, Inman BA. Obesity is associated with worse oncological outcomes in patients treated with radical cystectomy. BJU Int. 2013 Feb;111(2):187-8. doi: 10.1111/j.1464-410X.2012.11331.x. Epub 2012 Jun 21. PubMed PMID: 22727145.

Qi P, Tsivian M, Abern MR, Bañez LL, Tang P, Moul JW, Polascik TJ. Long-term oncological outcomes of men undergoing radical prostatectomy with preoperative prostate-specific antigen <2.5 ng/ml and 2.5-4 ng/ml. Urol Oncol. 2013 Nov;31(8):1527-32. doi: 10.1016/j.urolonc.2012.06.003. Epub 2012 Jul 12. PubMed PMID: 22795501.

Abern MR, Aronson WJ, Terris MK, Kane CJ, Presti JC Jr, Amling CL, Freedland  SJ. Delayed radical prostatectomy for intermediate-risk prostate cancer is associated with biochemical recurrence: possible implications for active surveillance from the SEARCH database. Prostate. 2013 Mar;73(4):409-17. doi: 10.1002/pros.22582. Epub 2012 Sep 19. PubMed PMID: 22996686.

Benson JS, Abern MR, Larsen S, Levine LA. Does a positive response to spermatic cord block predict response to microdenervation of the spermatic cord for chronic scrotal content pain? J Sex Med. 2013 Mar;10(3):876-82. doi: 10.1111/j.1743-6109.2012.02937.x. Epub 2012 Sep 27. PubMed PMID: 23016953.

Abern MR, Freedland SJ. Prostate cancer antigen 3 to select men for prostate biopsy: stop, go, or proceed with caution? Eur Urol. 2013 Feb;63(2):210-1; discussion 212-3. doi: 10.1016/j.eururo.2012.09.002. Epub 2012 Sep 10. PubMed PMID: 23018162.

Tsivian M, Bañez LL, Keto CJ, Abern MR, Qi P, Gerber L, Moul JW, Polascik TJ. African-American men with low-grade prostate cancer have higher tumor burdens: results from the Duke Prostate Center. Prostate Cancer Prostatic Dis. 2013 Mar;16(1):91-4. doi: 10.1038/pcan.2012.39. Epub 2012 Oct 2. PubMed PMID: 23032361.

Abern MR, Bassett MR, Tsivian M, Bañez LL, Polascik TJ, Ferrandino MN, Robertson CN, Freedland SJ, Moul JW. Race is associated with discontinuation of active surveillance of low-risk prostate cancer: results from the Duke Prostate Center. Prostate Cancer Prostatic Dis. 2013 Mar;16(1):85-90. doi: 10.1038/pcan.2012.38. Epub 2012 Oct 16. PubMed PMID: 23069729.

Tsivian M, Abern MR, Polascik TJ. Evolution of the concept of focal therapy for prostate cancer. Oncology (Williston Park). 2013 Jan;27(1):64-8, 70; discussion 70. Review. PubMed PMID: 23461042.

Ross SS, Masko EM, Abern MR, Allott EH, Routh JC, Wiener JS, Preminger GM, Freedland SJ, Lipkin ME. The effect of dietary sodium and fructose intake on urine and serum parameters of stone formation in a pediatric mouse model: a pilot study. J Urol. 2013 Oct;190(4 Suppl):1484-9. doi: 10.1016/j.juro.2013.02.3199. Epub 2013 Mar 7. PubMed PMID: 23473903.

Inman BA, Abern MR. Interpreting a study on bladder cancer screening. Eur Urol. 2013 Jul;64(1):48-50. doi: 10.1016/j.eururo.2013.03.047. Epub 2013 Apr 11.  PubMed PMID: 23582948.

Abern MR, Owusu RA, Anderson MR, Rampersaud EN, Inman BA. Perioperative intravesical chemotherapy in non-muscle-invasive bladder cancer: a systematic review and meta-analysis. J Natl Compr Canc Netw. 2013 Apr 1;11(4):477-84. Review. PubMed PMID: 23584348.

Tsivian M, Abern MR, Qi P, Polascik TJ. Short-term functional outcomes and complications associated with transperineal template prostate mapping biopsy. Urology. 2013 Jul;82(1):166-70. doi: 10.1016/j.urology.2013.01.071. Epub 2013 May 19. PubMed PMID: 23697794.

Tsivian M, Abern MR, Yoo JJ, Evans P, Qi P, Kim CY, Lipkin ME, Polascik TJ, Ferrandino MN. Radiation exposure associated with dedicated renal mass computed tomography protocol: impact of patient characteristics. J Endourol. 2013 Sep;27(9):1102-6. doi: 10.1089/end.2013.0111. Epub 2013 Aug 9. PubMed PMID: 23682980.

Qi P, Tsivian M, Abern MR, Passoni NM, McGinley KF, Polascik TJ. Clinicopathological characteristics and outcomes of surgically excised renal masses in African Americans. Urol Oncol. 2014 Jul;32(5):555-60. doi: 10.1016/j.urolonc.2013.11.011. Epub 2014 Feb 2. PubMed PMID: 24495445.

Abern MR, Scosyrev E, Tsivian M, Messing EM, Polascik TJ, Dudek AZ. Survival  of patients undergoing cytoreductive surgery for metastatic renal cell carcinoma  in the targeted-therapy era. Anticancer Res. 2014 May;34(5):2405-11. PubMed PMID: 24778051.

Tsivian M, Gupta RT, Tsivian E, Qi P, Mendez MH, Abern MR, Tay KJ and Polascik TJ: Assessing clinically significant prostate cancer: diagnostic properties of multiparametric magnetic resonance imaging compared to 3-dimensional transperineal template mapping histopathology. Int J Urol 2017: 24(2): 137-143.  PMID: 27859637.

Kathleen McGinley, DO

Qi P, Tsivian M, Abern MR, Passoni NM, McGinley KF, Polascik TJ. Clinicopathological characteristics and outcomes of surgically excised renal masses in African Americans. Urol Oncol. 2014 Jul;32(5):555-60. doi: 10.1016/j.urolonc.2013.11.011. Epub 2014 Feb 2. PubMed PMID: 24495445.

McGinley KF, Polascik BW and Polascik TJ: Ultrasound-guided prostate cryotherapy. In Advances in Image-Guided Urologic Surgery, ch 11, edited by Liao JC and Su LM, Springer, New York Sept 2014 [published November 18, 2014].

McGinley KF, McMahon GC, Brown GA. Impact of the US Preventive Services Task Force Grade D Recommendation: Assessment of Evaluations for Elevated Prostate-specific Antigen and Prostate Biopsies in a Large Urology Group Practice Following Statement Revision. Rev Urol. 2015;17(3):171-7. PubMed PMID: 26543432;  PubMed Central PMCID: PMC4633661.

McGinley KF, Sun X, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ. Utilization and impact of surgical technique on the performance of pelvic lymph node dissection at radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital database. Int J Urol. 2016  Mar;23(3):241-6. doi: 10.1111/iju.13027. Epub 2015 Dec 14. PubMed PMID: 26667212.

McGinley KF, Tay KJ, Moul JW. Prostate cancer in men of African origin. Nat Rev Urol. 2016 Feb;13(2):99-107. doi: 10.1038/nrurol.2015.298. Epub 2015 Dec 31.  Review. PubMed PMID: 26718455.

Longo T, McGinley KF, Freedman JA, Etienne W, Wu Y, Sibley A, Owzar K, Gresham J, Moy C, Szabo S, Greshock J, Zhou H, Bai Y, Inman BA. Targeted Exome Sequencing of the Cancer Genome in Patients with Very High-risk Bladder Cancer. Eur Urol. 2016 Nov;70(5):714-717. doi: 10.1016/j.eururo.2016.07.049. Epub 2016 Aug 9. PubMed PMID: 27520487.

Kathleen F. McGinley and Edward N. Rampersaud.  Testicular Cancer. In A. Merseburger, M.A. Kuczyk, J.W. Moul (eds): Urology at a Glance – From Symptoms to Therapy.

Kathleen F. McGinley, Anthony Viera, and Stephen J. Freedland. Characterization of a “Low-Risk” Cohort of Gleason 7 Prostate Cancer Patients. Master’s Thesis, University of North Carolina Gillings School of Global Public Health, 2015.

Kae Jack Tay, MD

Tay KJ, Mendez M, Moul JW, Polascik TJ. Active surveillance for prostate cancer: can we modernize contemporary protocols to improve patient selection and outcomes in the focal therapy era? Curr Opin Urol. 2015 May;25(3):185-90. doi: 10.1097/MOU.0000000000000168. Review. PubMed PMID: 25768694.

Polascik TJ, Tay KJ, Moul JW. Keeping an Open Mind About Novel Concepts for Management of Prostate Cancer. Eur Urol. 2015 Dec;68(6):937-8. doi: 10.1016/j.eururo.2015.02.024. Epub 2015 Mar 11. PubMed PMID: 25770483.

Inman B, Tay KJ. Inflammation: A Significant Contributor to Upper-tract Urothelial Carcinoma Prognosis? Eur Urol Focus. 2015 Aug;1(1):64-65. doi: 10.1016/j.euf.2015.02.004. Epub 2015 May 16. PubMed PMID: 28723358.

Tay KJ, Polascik TJ, Elshafei A, Cher ML, Given RW, Mouraviev V, Ross AE, Jones JS. Primary Cryotherapy for High-Grade Clinically Localized Prostate Cancer: Oncologic and Functional Outcomes from the COLD Registry. J Endourol. 2016 Jan;30(1):43-8. doi: 10.1089/end.2015.0403. Epub 2015 Oct 20. PubMed PMID: 26414656.

Tay KJ, Gupta RT, Brown AF, Silverman RK, Polascik TJ. Defining the Incremental Utility of Prostate Multiparametric Magnetic Resonance Imaging at Standard and Specialized Read in Predicting Extracapsular Extension of Prostate Cancer. Eur Urol. 2016 Aug;70(2):211-3. doi: 10.1016/j.eururo.2015.10.041. Epub 2015 Nov 6. PubMed PMID: 26553331.

Tay KJ, Moul JW, Armstrong AJ. Management of Prostate Cancer in the Elderly. Clin Geriatr Med. 2016 Feb;32(1):113-32. doi: 10.1016/j.cger.2015.08.001. Epub 2015 Oct 14. Review. PubMed PMID: 26614864.

Polascik TJ, Tay KJ, Ghai S, Jimenez RE, Kench J, Klotz L, Montironi R, Muto S, Rastinehad AR, Turkbey B, Villers A, Amin MB: Surveillance after prostate focal therapy.”  International Consensus of Urologic Disease (ICUD), 2015.

McGinley KF, Tay KJ, Moul JW. Prostate cancer in men of African origin. Nat Rev Urol. 2016 Feb;13(2):99-107. doi: 10.1038/nrurol.2015.298. Epub 2015 Dec 31.  Review. PubMed PMID: 26718455.

Tay KJ, Gupta RT, Rastinehad AR, Tsivian E, Freedland SJ, Moul JW and Polascik TJ: Navigating MRI-TRUS fusion biopsy: optimizing the process and avoiding technical pitfalls. Expert Rev Anticancer Ther 16(3): 303-11, 2016, PMID: 26653079.

Postema AW, De Reijke TM, Ukimura O, Van den Bos W, Azzouzi AR, Barret E, Baumunk D, Blana A, Bossi A, Brausi M, Coleman JA, Crouzet S, Dominguez-Escrig J, Eggener S, Ganzer R, Ghai S, Gill IS, Gupta RT, Henkel TO, Hohenfellner M, Jones JS, Kahmann F, Kastner C, Köhrmann KU, Kovacs G, Miano R, van Moorselaar RJ, Mottet N, Osorio L, Pieters BR, Polascik TJ, Rastinehad AR, Salomon G, Sanchez-Salas R, Schostak M, Sentker L, Tay KJ, Varkarakis IM, Villers A, Walz J, De la Rosette JJ. Standardization of definitions in focal therapy of prostate cancer: report from a Delphi consensus project. World J Urol. 2016 Oct;34(10):1373-82. doi: 10.1007/s00345-016-1782-x. Epub 2016 Feb 18. Review. PubMed PMID: 26892160; PubMed Central PMCID: PMC5026990.

Kovac E, ElShafei A, Tay KJ, Mendez M, Polascik TJ, Jones JS. Five-Year Biochemical Progression-Free Survival Following Salvage Whole-Gland Prostate Cryoablation: Defining Success with Nadir Prostate-Specific Antigen. J Endourol.  2016 Jun;30(6):624-31. doi: 10.1089/end.2015.0719. Epub 2016 Apr 5. PubMed PMID: 26915721.

Gupta RT, Brown AF, Silverman RK, Tay KJ, Madden JF, George DJ, Polascik TJ. Can Radiologic Staging With Multiparametric MRI Enhance the Accuracy of the Partin Tables in Predicting Organ-Confined Prostate Cancer? AJR Am J Roentgenol. 2016 Jul;207(1):87-95. doi: 10.2214/AJR.15.15878. Epub 2016 Apr 11. PubMed PMID: 27064383.

Polascik TJ, Tay KJ. Editorial Comment. J Urol. 2016 Sep;196(3):889. doi: 10.1016/j.juro.2016.02.3001. Epub 2016 Jun 1. PubMed PMID: 27260991.

Holtz JN, Tay KJ, Polascik TJ, Gupta RT. Integration of multiparametric MRI into active surveillance of prostate cancer. Future Oncol. 2016 Nov;12(21):2513-2529. Epub 2016 Jun 20. Review. PubMed PMID: 27322161.

Tay KJ, Polascik TJ. Focal Cryotherapy for Localized Prostate Cancer. Arch Esp Urol. 2016 Jul;69(6):317-26. Review. PubMed PMID: 27416635.

Tay KJ, Villers A, Polascik TJ. Targeted Anterior Gland Focal Therapy-a Novel Treatment Option for a Better Defined Disease. Curr Urol Rep. 2016 Oct;17(10):69. doi: 10.1007/s11934-016-0628-9. Review. PubMed PMID: 27502428.

Scheltema MJ, Tay KJ, Postema AW, de Bruin DM, Feller J, Futterer JJ, George AK, Gupta RT, Kahmann F, Kastner C, Laguna MP, Natarajan S, Rais-Bahrami S, Rastinehad AR, de Reijke TM, Salomon G, Stone N, van Velthoven R, Villani R, Villers A, Walz J, Polascik TJ, de la Rosette JJMCH. Utilization of multiparametric prostate magnetic resonance imaging in clinical practice and focal therapy: report from a Delphi consensus project. World J Urol. 2017 May;35(5):695-701. doi: 10.1007/s00345-016-1932-1. Epub 2016 Sep 16. PubMed PMID: 27637908; PubMed Central PMCID: PMC5397427.

Tsivian M, Gupta RT, Tsivian E, Qi P, Mendez MH, Abern MR, Tay KJ, Polascik TJ. Assessing clinically significant prostate cancer: Diagnostic properties of multiparametric magnetic resonance imaging compared to three-dimensional transperineal template mapping histopathology. Int J Urol. 2017 Feb;24(2):137-143. doi: 10.1111/iju.13251. Epub 2016 Nov 8. PubMed PMID: 27859637.

Schulman AA, Tay KJ, Robertson CN, Polascik TJ. High-intensity focused ultrasound for focal therapy: reality or pitfall? Curr Opin Urol. 2017 Mar;27(2):138-148. doi: 10.1097/MOU.0000000000000372. PubMed PMID: 27997415.

Schulman AA, Tay KJ, Polascik TJ. Expanding thermal ablation to the 'intermediate-sized' renal mass: clinical utility in T1b tumors. Transl Androl Urol. 2017 Feb;6(1):127-130. doi: 10.21037/a

DJ, Arora HC, Given RW, Tay KJ, Polascik TJ, Ross AE, Mouraviev VB, Lugnani F, Jones JS. Prostate Specific Antigen Nadir of 0.1 or Less Is a Predictor of Treatment Success in Men Undergoing Salvage Whole Prostate Gland Cryoablation. J Endourol. 2017 May;31(5):497-501. doi: 10.1089/end.2016.0715. PubMed PMID: 28437170.

Tay KJ, Gupta RT, Holtz J, Silverman RK, Tsivian E, Schulman A, Moul JW, Polascik TJ. Does mpMRI improve clinical criteria in selecting men with prostate cancer for active surveillance? Prostate Cancer Prostatic Dis. 2017 Sep;20(3):323-327. doi: 10.1038/pcan.2017.20. Epub 2017 Apr 25. PubMed PMID: 28440322.

Tay KJ, Schulman AA, Sze C, Tsivian E, Polascik TJ. New advances in focal therapy for early stage prostate cancer. Expert Rev Anticancer Ther. 2017 Aug; 17(8):737-743. doi: 10.1080/14737140.2017.1345630. Epub 2017 Jun 28. Review. PubMed PMID: 28635336.

Schulman AA, Howard LE, Tay KJ, Tsivian E, Sze C, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ, Polascik TJ. Validation of the 2015 prostate cancer grade groups for predicting long-term oncologic outcomes in a shared equal-access health system. Cancer. 2017 Nov 1;123(21):4122-4129. doi: 10.1002/cncr.30844. Epub 2017 Jun 29. PubMed PMID: 28662291.

Holtz JN, Silverman RK, Tay KJ, Browning JT, Huang J, Polascik TJ, Gupta RT. New prostate cancer prognostic grade group (PGG): Can multiparametric MRI (mpMRI) accurately separate patients with low-, intermediate-, and high-grade cancer? Abdom Radiol (NY). 2017 Jul 18. doi: 10.1007/s00261-017-1255-8. [Epub ahead of print] PubMed PMID: 28721479.

Tay KJ and Polascik TJ: Anterior prostate cancer cryoablation: a technique in prostate focal therapy. Videourology: 31, No 2, April 2017.

El Shafei A, Lugnani F, Nyame Y, Arora H, Patel S, Tay KJ, Polascik TJ, Jones JS: Associations between prostate volume and oncological outcomes in men undergoing focal cryoablation of the prostate. In press, Clinical Genitourinary Cancer 2017.

Tay KJ, Amin MB, Ghai S, Jimenez RE, Kench JG, Klotz LH, Montironi R, Muto S, Rastinehad AR, Turkbey B, Villers A and Polascik TJ: Surveillance after prostate focal therapy.  World Journal of Urology, submitted Oct 2017.

Tay KJ, Kim C, and Polascik TJ: ch 29 Renal Cryosurgery. In: Hinman’s Atlas of Urologic Surgery, Fourth Edition. Edited by JA Smith, SS Howards, GM Preminger and RM Dmochowski. Elsevier, Philadelphia, PA, 2016.

Tay KJ, Tsivian M and Polascik TJ: Prostate Cryotherapy.  In: Management of Prostate Cancer – A Multidisciplinary Approach, 2nd ed, Edited by Bolla M and Van poppel H, Springer Aug 2016.

Tay KJ and Polascik TJ: Focal therapy for prostate cancer: A guide for patients.  In: Imaging and Focal Therapy of Early Prostate Cancer, 2ed., edited by TJ Polascik, Current Clinical Urology, Humana Press, Springer, New York, NY, 2016.

Tay KJ and Polascik TJ: Focal therapy of prostate cancer.  Smith’s Textbook of Endourology, fourth ed., Edited by Smith A, Preminger G, Kavoussi L and Badlani G.  Wiley, 2016.

Tay KJ, Tsivian E and Polascik TJ: Focal Cryotherapy.  In: Imaging and Focal Therapy of Early Prostate Cancer, 2ed., edited by TJ Polascik, Current Clinical Urology, Humana Press, Springer, New York, NY, 2016.

Polascik TJ and Tay KJ: Editorial comment.  J Urol 2016 May 31.doi: 10.1016/j.juro.2016.02.3001.  PMID: 27260991.

Polascik TJ and Tay KJ: Commentary on “Focal therapies in the treatment of prostate cancer.” Hinman’s Atlas of Urologic Surgery 4th ed 2016

Dr. Tay has several other manuscripts in preparation and pending publication

Thomas A. Longo MD

Qi R, Foo WC, Ferrandino MN, Davis LG, Sekar S, Longo TA, Jibara G, Han T, Gokhan I, Moul JW.  Over half of contemporary clinical Gleason 8 on prostate biopsy are downgraded at radical prostatectomy. Can J Urol. 2017 Oct;24(5):8982-8989.   PMID: 28971784.

Gopalakrishna A, Longo TA, Fantony JJ, Harrison MR, Inman BA.  Physical activity patterns and associations with health-related quality of life in bladder cancer survivors.  Urol Oncol. 2017 Sep;35(9):540.e1-540.e6. doi: 10.1016/j.urolonc.2017.04.016. Epub 2017 May 17. PMID: 28527621.

Tsivian E, Tsivian M, Tay KJ, Longo T, Zukerman Z, Martorana G, Schiavina R, Brunocilla E, Polascik TJ.  Body mass index and the clinicopathological characteristics of clinically localized renal masses-An international retrospective review.  Urol Oncol. 2017 Jul;35(7):459.e1-459.e5. doi: 10.1016/j.urolonc.2017.02.004. Epub 2017 Mar 18. PMID: 28284892.

Fantony JJ, Longo TA, Gopalakrishna A, Owusu R, Lance RS, Foo WC, Inman BA, Abern MR.  Urinary NID2 and TWIST1 methylation to augment conventional urine cytology for the detection of bladder cancer.  Cancer Biomark. 2017;18(4):381-387. doi: 10.3233/CBM-160261. PMID: 28106542.

Gopalakrishna A, Fantony JJ, Longo TA, Owusu R, Foo WC, Dash R, Denton BT, Inman BA. Anticipatory Positive Urine Tests for Bladder Cancer.  Ann Surg Oncol. 2017 Jun;24(6):1747-1753. doi: 10.1245/s10434-016-5763-5. Epub 2017 Jan 10.  PMID: 28074325.

Inman BA, Longo TA, Ramalingam S, Harrison MR.  Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer.  Clin Cancer Res. 2017 Apr 15;23(8):1886-1890. doi: 10.1158/1078-0432.CCR-16-1417. Epub 2016 Nov 30. Review.  PMID: 27903674.

Longo T, McGinley KF, Freedman JA, Etienne W, Wu Y, Sibley A, Owzar K, Gresham J, Moy C, Szabo S, Greshock J, Zhou H, Bai Y, Inman BA. Targeted Exome Sequencing of the Cancer Genome in Patients with Very High-risk Bladder Cancer.  Eur Urol. 2016 Nov;70(5):714-717. doi: 10.1016/j.eururo.2016.07.049. Epub 2016 Aug 9.  PMID: 27520487.

Gopalakrishna A, Longo TA, Fantony JJ, Owusu R, Foo WC, Dash R, Inman BA.  The diagnostic accuracy of urine-based tests for bladder cancer varies greatly by patient. BMC Urol. 2016 Jun 13;16(1):30. doi: 10.1186/s12894-016-0147-5.  PMID: 27296150.

Gopalakrishna A, Longo TA, Fantony JJ, Doshi U, Harrison MR, Van Noord M, Inman BA. High rates of venous thromboembolic events in patients undergoing systemic therapy for urothelial carcinoma: A systematic review and meta-analysis.  Urol Oncol. 2016 Sep;34(9):407-14. doi: 10.1016/j.urolonc.2016.05.009. Epub 2016 Jun 4. Review.  PMID: 27267581.

Longo TA, Gopalakrishna A, Tsivian M, Van Noord M, Rasch CR, Inman BA, Geijsen ED. A systematic review of regional hyperthermia therapy in bladder cancer.  Int J Hyperthermia. 2016 Jun;32(4):381-9. doi: 10.3109/02656736.2016.1157903. Epub 2016 May 1. PMID: 27134130.

Gopalakrishna A, Longo TA, Fantony JJ, Van Noord M, Inman BA.  Lifestyle factors and health-related quality of life in bladder cancer survivors: a systematic review.  J Cancer Surviv. 2016 Oct;10(5):874-82. doi: 10.1007/s11764-016-0533-8. Epub 2016 Mar 21. Review. PMID: 27002077.

T Longo: “Urinary Biomarkers for Bladder Cancer.” In  "Precision Molecular Pathology of Bladder Cancer" edited by Seth Lerner and Donna Hansel, 2018.

Ariel Schulman, MD

Mouraviev V, Villers A, Wheeler TM, Montironi R, Nevoux P, Schulman A and Polascik TJ: Pathologic rationale for focal therapy of prostate cancer: Elucidating tumor characteristics and biology.  In: Imaging and Focal Therapy of Early Prostate Cancer, 2ed., edited by TJ Polascik, Current Clinical Urology, Humana Press, Springer, New York, NY, 2016.

Tay KJ, Gupta RT, Holtz J, Silverman RK, Tsivian E, Schulman A, Moul JW and Polascik TJ:  Does mpMRI improve clinical criteria in selecting men with prostate cancer for active surveillance? Prostate Cancer Prostatic Dis, 20(3): 323-327, 2017.  PMID: 28440322.

Schulman AA, Polascik TJ. Most of patients with localized prostate cancer will be treated in the future? | Opinion: No. Int Braz J Urol. 2017 Jul-Aug;43(4):584-587. doi: 10.1590/S1677-5538.IBJU.2017.04.03. PubMed PMID: 28783263; PubMed Central PMCID: PMC5557432.

Tay KJ, Schulman AA, Sze C, Tsivian E, Polascik TJ. New advances in focal therapy for early stage prostate cancer. Expert Rev Anticancer Ther. 2017 Aug;17(8):737-743. doi: 10.1080/14737140.2017.1345630. Epub 2017 Jun 28. Review.  PubMed PMID: 28635336.

Schulman AA, Howard LE, Tay KJ, Tsivian E, Sze C, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ and Polascik TJ: Validation of the 2015 prostate cancer grade groups for predicting long-term oncologic outcomes in a Shared Equal-Access Health System. Cancer, 123(21): 4122-4129, 2017 Jun 29. doi: 10.1002/cncr.30844. [Epub ahead of print].  PMID: 28662291.

Schulman AA, Sze C, Tsivian E, Gupta RT, Moul JW, Polascik TJ. The Contemporary Role of Multiparametric Magnetic Resonance Imaging in Active Surveillance for Prostate Cancer. Curr Urol Rep. 2017 Jul;18(7):52. doi: 10.1007/s11934-017-0699-2. Review. PubMed PMID: 28589398.

Schulman AA, Tay KJ, Polascik TJ. Expanding thermal ablation to the 'intermediate-sized' renal mass: clinical utility in T1b tumors. Transl Androl Urol. 2017 Feb;6(1):127-130. doi: 10.21037/tau.2017.01.08. PubMed PMID: 28217461; PubMed Central PMCID: PMC5313302..

Schulman AA, Tay KJ, Robertson CN, Polascik TJ. High-intensity focused ultrasound for focal therapy: reality or pitfall? Curr Opin Urol. 2017 Mar;27(2):138-148. doi: 10.1097/MOU.0000000000000372. PubMed PMID: 27997415.

Patel MP, Schulman A, Shah KP, Anderson JB, and Polascik TJ: Engaging the primary care community to encourage appropriate prostate cancer screening. Therapeutic Advances in Urology, 2017

Dr Schulman has multiple manuscripts in preparation and submission at this time.

Ali Aminsharifi, MD

Aminsharifi A, Kotamarti S, Silver D, Schulman A. Major Complications and Adverse Events Related to the Injection of the SpaceOAR Hydrogel System Before Radiotherapy for Prostate Cancer: Review of the Manufacturer and User Facility Device Experience Database. J Endourol. 2019 Oct;33(10):868-871.

Aminsharifi A, Polascik TJ. Diagnosis and Management of Local Recurrence After Prostate Focal Therapy: Challenges and Solutions. Eur Urol Oncol. 2019;2(5):539-540.

Aminsharifi A, Jibara G, Tsivian E, Tsivian M, Elshafei A, Polascik TJ. Salvage Prostate Cryoablation for the Management of Local Recurrence After Primary Cryotherapy: A Retrospective Analysis of Functional and Intermediate-Term Oncological Outcomes Associated With a Second Therapeutic Freeze. Clin Genitourin Cancer 2019 ;17(4):e831-e836.

Aminsharifi A, Schulman A, Howard LE, Tay KJ, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ, Polascik TJ. Influence of African American race on the association between preoperative biopsy grade group and adverse histopathologic features of radical prostatectomy. Cancer 2019;125(17):3025-3032

Aminsharifi A, Simon R, Polascik TJ, Robertson CN, Sudan DL, Collins BH, Moul JW. Evaluation and active treatment versus active surveillance of localized prostate cancer in renal transplant patients in the era of low and very low risk prostate cancer. J Urol. 2019 Sep;202(3):469-474.

Faraji SN, Nejatollahi F, Tamaddon AM, Mohammadi M, Aminsharifi A. Generation and characterization of a specific single-chain antibody against DSPP as a prostate cancer biomarker: Involvement of bioinformatics-based design of novel epitopes. Int Immunopharmacol. 2019 Feb; 69: 217-24

Aminsharifi A, Gupta RT, Tsivian E, Sekar S, Sze C, Polascik TJ. Reduced Core Targeted (RCT) biopsy: Combining multiparametric magnetic resonance imaging -transrectal ultrasound fusion targeted biopsy with laterally-directed sextant biopsies - An alternative template for prostate fusion biopsy. Eur J Radiol. 2019 Jan;110:7-13.

Aminsharifi A, Howard LE, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Polascik TJ, Freedland SJ. Statins are Associated With Increased Biochemical Recurrence After Radical Prostatectomy in Diabetic Men but no Association was Seen in Men also Taking Metformin: Results From the SEARCH Database. Clin Genitourin Cancer. 2019 Feb; 17(1):e140-e149.

Aminsharifi A, de la Rosette J, Polascik TJ. Focal therapy of prostate and kidney cancer. Curr Opin Urol. 2018 Nov;28(6):491-492

Aminsharifi A, Gupta RT, Huang J, Polascik TJ. Three-dimensional localization and targeting of prostate cancer foci with imaging and histopathologic correlation: establishing a multidisciplinary team for quality improvement. Curr Opin Urol. 2018 Nov;28(6):506-511.

Aminsharifi A, Schulman A, Anderson J, Fish L, Oeffinger K, Shah K, Sze C, Tay KJ, Tsivian E, Polascik TJ. Primary care perspective and implementation of a multidisciplinary, institutional prostate cancer screening algorithm embedded in  the electronic health record. Urol Oncol. 2018 Nov;36(11):502.e1-502.e6.

Aminsharifi A, Polascik TJ, Tsivian M, Schulman A, Tsivian E, Tay KJ, Elshafei A, Jones JS. Does Any Racial Disparity Exist in Oncologic Outcomes After Primary Cryotherapy for Prostate Cancer? A Matched-pair Comparative Analysis of the Cryo  On-Line Data Registry. Clin Genitourin Cancer. 2018 Oct;16(5):e1073-e1076.

Aminsharifi A, Polascik TJ, Schulman A, Tay KJ, Jibara G, Sze C, Tsivian E, Elshafei A, Jones JS. Predictors of Rectourethral Fistula Formation After Primary Whole-Gland Cryoablation for Prostate Cancer: Results from the Cryo On-Line Database Registry. J Endourol. 2018 Sep 12;32(9):791-796.

Aminsharifi A, Polascik TJ. RE:Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy with Brachytherapy Boost and Disease Progression and Mortality in Patients with Gleason Score 9-10 Prostate Cancer. Eur Urol. 2018 Oct;74(4):526.

Aminsharifi A, Howard L, Wu Y, De Hoedt A, Bailey C, Freedland SJ, Polascik TJ. Prostate Specific Antigen Density as a Predictor of Clinically Significant Prostate Cancer When the Prostate Specific Antigen is in the Diagnostic Gray Zone: Defining the Optimum Cutoff Point Stratified by Race and Body Mass Index. J Urol. 2018 Oct;200(4):758-766.

Aminsharifi A, Brousell SC, Chang A, León J, Inman BA. Heat-targeted drug delivery: A promising approach for organsparing treatment of bladder cancer.THERMODOX®. Arch Esp Urol. 2018 May;71(4):447-452.

Aminsharifi A, Polascik TJ. Editorial Comment. J Urol. 2018 Jun;199(6):1508-1509.

Aminsharifi A, Polascik TJ. RE:Prevalence and Prognosis of Low-volume, Oligorecurrent, Hormone-sensitive Prostate Cancer Amenable to Lesion Ablative Therapy. Eur Urol. 2018 Aug 74 (2): 234-5.